Clinical Trial Update: Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet [Phase 2]

View source ↗

Summary

This is a completed Phase 2b trial evaluating the one-year efficacy and safety of S-2367 in obese subjects after an initial six-week low-calorie diet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• S-2367

Snippet

Sponsor: Shionogi | Conditions: Obesity | Phase 2 | Status: COMPLETED